Table 4.

Pretreatment with Either Wortmannin or Ly294002 Does Not Enhance the Sensitivity of HL-60 PT Cells While It Restores the Sensitivity of HL-60 AR Cells to the Drugs

Cell TreatmentHL-60 PT (6 h)HL-60 AR (6 h)
None (control)4.8 ± 1.51.8 ± 0.6
Wortmannin alone (0.1 μm)5.2 ± 1.71.9 ± 1.6
Wortmannin + camptothecin (0.1 μg/ml)67.3 ± 7.150.3 ± 5.9
Wortmannin + etoposide (5 μg/ml)51.2 ± 6.027.6 ± 3.0
Wortmannin + doxorubicin (100 μg/ml)30.0 ± 3.323.4 ± 3.5
Wortmannin + cytarabine (40 μg/ml)45.1 ± 5.332.0 ± 4.1
Wortmannin + mitoxantrone (40 μg/ml)32.2 ± 3.325.5 ± 2.4
Wortmannin + vincristine (4 μg/ml)36.6 ± 4.226.6 ± 2.8
Ly294002 alone (5 μm)5.2 ± 1.62.1 ± 1.4
Ly294002 + camptothecin (0.1 μg/ml)69.2 ± 7.361.4 ± 6.7
Ly294002 + etoposide (5 μg/ml)50.6 ± 5.931.1 ± 3.3
Ly294002 + doxorubicin (100 μg/ml)31.1 ± 3.419.3 ± 2.7
Ly294002 + cytarabine (40 μg/ml)44.6 ± 4.937.7 ± 4.2
Ly294002 + mitoxantrone (40 μg/ml)31.7 ± 4.023.5 ± 2.3
Ly294002 + vincristine (4 μg/ml)37.7 ± 3.828.3 ± 2.9
  • Note: Incubation with the drugs was for 6 h. Data show the percentage of apoptotic cells and are the means ± SD from three separate experiments.